Literature DB >> 21921600

Characterization of direct and indirect cerebral revascularization for the treatment of European patients with moyamoya disease.

M Czabanka1, P Peña-Tapia, J Scharf, G A Schubert, E Münch, P Horn, P Schmiedek, P Vajkoczy.   

Abstract

BACKGROUND: The best revascularization strategy for moyamoya disease (MMD) remains unknown. Our aim was to characterize angiographic revascularization effects of a bilateral standardized revascularization approach, consisting of superficial temporal artery (STA)-middle cerebral artery (MCA) bypass and encephalomyosynangiosis (EMS) on one hemisphere and single EMS on the contralateral hemisphere of each patient, and to compare the effects of both revascularization strategies on cerebral hemodynamics.
METHODS: In 30 patients (18 females/12 males, age 8-63 years), standardized revascularization was performed. Digital subtraction angiography was performed preoperatively and at 7 days, 6 months and 12 months postoperatively. STA-MCA and EMS functions were graded I (poor), II (medium) or III (extensive) according to angiographic aspects. In 20 patients, cerebrovascular reserve capacity (CVRC) was assessed pre- and postoperatively (at 12 months) using xenon CT.
RESULTS: After 12 months, STA-MCA/EMS function was grade 1 in 40/40%, grade 2 in 27/26%, and grade 3 in 27/10% of hemispheres, respectively. Twelve months after surgery, single EMS showed grade I in 37%, grade II in 27%, and grade III in 20% of hemispheres. Combined revascularization improved CVRC significantly compared to preoperative measurement (preoperative: 16.5 ± 34.6% vs. postoperative: 60.8 ± 64.22%; p < 0.05). Single EMS did not improve CVRC significantly (preoperative: 21.8 ± 35.9% vs. postoperative: 34.8 ± 63.0%; p < 0.05).
CONCLUSIONS: Combined and indirect revascularization may be successfully applied in a bilateral standardized approach. STA-MCA/EMS is superior to single EMS in restoring CVRC in adult MMD patients.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 21921600     DOI: 10.1159/000330351

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  10 in total

1.  Balanced single-vector co-delivery of VEGF/PDGF-BB improves functional collateralization in chronic cerebral ischemia.

Authors:  Aiki Marushima; Melina Nieminen; Irina Kremenetskaia; Roberto Gianni-Barrera; Johannes Woitzik; Georges von Degenfeld; Andrea Banfi; Peter Vajkoczy; Nils Hecht
Journal:  J Cereb Blood Flow Metab       Date:  2019-01-09       Impact factor: 6.200

Review 2.  Surgical Treatment of Adult Moyamoya Disease.

Authors:  Si Un Lee; Chang Wan Oh; O-Ki Kwon; Jae Seung Bang; Seung Pil Ban; Hyoung Soo Byoun; Tackeun Kim
Journal:  Curr Treat Options Neurol       Date:  2018-05-28       Impact factor: 3.598

3.  Efficacy of STA-MCA bypass surgery in moyamoya angiopathy: long-term follow-up of the Caucasian Krupp Hospital cohort with 81 procedures.

Authors:  Markus Kraemer; Rusen Karakaya; Toshinori Matsushige; Jonas Graf; Philipp Albrecht; Hans-Peter Hartung; Peter Berlit; Rudolf Laumer; Frank Diesner
Journal:  J Neurol       Date:  2018-08-28       Impact factor: 4.849

4.  Clinical and angiographic outcomes after combined direct and indirect bypass in adult patients with moyamoya disease: A retrospective study of 76 procedures.

Authors:  Jinbing Zhao; Hongyi Liu; Yuanjie Zou; Wenbin Zhang; Shengxue He
Journal:  Exp Ther Med       Date:  2018-02-07       Impact factor: 2.447

5.  The Efficacy of Single Barrel Superficial Temporal Artery-middle Cerebral Artery Bypass in Treatment of Adult Patients with Ischemic-type Moyamoya Disease.

Authors:  Mahnjeong Ha; Chang Hwa Choi; Jae Il Lee; Seung Heon Cha; Sang Weon Lee; Jun Kyeung Ko
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2016-09-30

6.  Preservation of spatial memory and neuroprotection by the fatty acid amide hydrolase inhibitor URB597 in a rat model of vascular dementia.

Authors:  Da-Peng Wang; Qi Lin; Kai Kang; Yi-Fang Wu; Shao-Hua Su; Jian Hai
Journal:  Ann Transl Med       Date:  2021-02

7.  Pediatric Moyamoya Disease and Syndrome in Italy: A Multicenter Cohort.

Authors:  Chiara Po'; Margherita Nosadini; Marialuisa Zedde; Rosario Pascarella; Giuseppe Mirone; Domenico Cicala; Anna Rosati; Alessandra Cosi; Irene Toldo; Raffaella Colombatti; Paola Martelli; Alessandro Iodice; Patrizia Accorsi; Lucio Giordano; Salvatore Savasta; Thomas Foiadelli; Giuseppina Sanfilippo; Elvis Lafe; Federico Zappoli Thyrion; Gabriele Polonara; Serena Campa; Federico Raviglione; Barbara Scelsa; Stefania Maria Bova; Filippo Greco; Duccio Maria Cordelli; Luigi Cirillo; Francesco Toni; Valentina Baro; Francesco Causin; Anna Chiara Frigo; Agnese Suppiej; Laura Sainati; Danila Azzolina; Manuela Agostini; Elisabetta Cesaroni; Luigi De Carlo; Gabriella Di Rosa; Giacomo Esposito; Luisa Grazian; Giovanna Morini; Francesco Nicita; Francesca Felicia Operto; Dario Pruna; Paola Ragazzi; Massimo Rollo; Alberto Spalice; Pasquale Striano; Aldo Skabar; Luigi Alberto Lanterna; Andrea Carai; Carlo Efisio Marras; Renzo Manara; Stefano Sartori
Journal:  Front Pediatr       Date:  2022-05-06       Impact factor: 3.418

8.  Surgical Management of Failed Revascularization in Moyamoya Vasculopathy.

Authors:  Kristin Lucia; Güliz Acker; Nicolas Schlinkmann; Stefan Georgiev; Peter Vajkoczy
Journal:  Front Neurol       Date:  2021-06-29       Impact factor: 4.003

9.  The Efficacy of Surgical Treatment for the Secondary Prevention of Stroke in Symptomatic Moyamoya Disease: A Meta-Analysis.

Authors:  Cong Qian; Xiaobo Yu; Jianru Li; Jingyin Chen; Lin Wang; Gao Chen
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

Review 10.  Implementation and Rationale for a Unified Clinical and Imaging Protocol for Evaluation and Treatment of Moyamoya Angiopathy: A Single Institutional Experience.

Authors:  Anthony S Larson; Vance T Lehman; Luis E Savastano; Giuseppe Lanzino; Norbert G Campeau; Kirk M Welker; James P Klaas
Journal:  Front Neurol       Date:  2021-05-17       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.